MedTrace Logo

Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes

NCT01285518 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2016-11-18

Study results available
· View outcomes & findings →

Summary

This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

PF-05231023

0.5 mg QD IV x 1 day

DRUG

PF-05231023

1.5 mg QD IV x 1 day

DRUG

PF-05231023

5 mg QD IV x 1 day

DRUG

PF-05231023

15 mg QD IV x 1 day

DRUG

PF-05231023

50 mg QD IV x 1 day

DRUG

PF-05231023

100 mg QD IV x 1 day

DRUG

PF-05231023

200 mg QD IV x 1 day

OTHER

Placebo

0.9% w/v sodium chloride injection, USP QD IVx 1 day

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285518 on ClinicalTrials.gov